With CancerIFP, nine tumor-specific proteins (CD45, PD-L1, LAG3, p-mTOR, p-ERK, p16, p53, HER2, TROP2) are analyzed on a single FFPE tissue section.
In contrast to conventional immunohistochemistry (IHC), which typically detects only one marker per tissue section, CancerIFP enables the parallel analysis of nine markers. Each marker is detected using a specific antibody labeled with a distinct fluorescent dye. The antibodies bind selectively to defined proteins within the tissue. During imaging, the fluorescence signals are digitally captured and visualized separately. This allows us to simultaneously evaluate multiple markers and clearly asses their spatial distribution within the tumor tissue.
With the parallel analysis of multiple markers on a single tissue section, CancerIFP provides a tissue-sparing approach to protein expression analysis. This is particularly useful when only limited tumor tissue is available or when additional analyses are planned.
Benefit from:
- comprehensive insights through the analysis of multiple markers on a single tissue section
- a clear overview of immune checkpoint expression and the tumor microenvironment
- deeper insights into tumor-associated signaling pathways
- the ability to validate DNA or RNA findings at the protein level
All marker analyses are performed on our whole-slide immunofluorescence platform and reviewed by a specialist in neuropathology or pathology. We have developed the assay in-house as a laboratory-developed test (LDT). Each antibody has been internally validated, and evaluation follows a consistent scoring system based on established IHC standards.
CancerIFP provides a detailed view of protein expression in tumor tissue and complements DNA- and RNA-based results with protein-level findings. The service can be ordered as an add-on to our comprehensive tumor diagnostics services, CancerPrecision® and CancerNeo®.
Our experts will be pleased to support you in selecting the most suitable diagnostic strategy. Call us at +49 (0) 7071 565 44 55 or email us at tumor@cegat.com.